# SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

> **NCT07470840** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Renal Cell Carcinoma

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **DRUG:** Anlotinib
- **DRUG:** Bemarituzumab

## Key facts

- **NCT ID:** NCT07470840
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-01
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07470840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07470840, "SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07470840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*